Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 20 - F ( Mark One ) ㅁ REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 ☑ ㅁ OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31 , 2021 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number 001-35463 TARO PHARMACEUTICAL INDUSTRIES LTD . ( Exact name of Registrant as specified in its charter ) N / A ( Translation of Registrant's name into English ) Israel ( Jurisdiction of incorporation or organization ) 14 Hakitor Street , Haifa Bay 2624761 , Israel ( Address of principal executive offices ) Daphne Huang Chief Financial Officer Taro Pharmaceutical Industries Ltd. c / o Taro Pharmaceuticals U.S.A. , Inc. 3 Skyline Drive Hawthorne , NY 10532 Tel : 914-345-9000 Fax : 914-345-6169 Email : Daphne.Huang@Taro.com ( Name , telephone , email and / or facsimile number and address of Company contact person )